16 Participants Needed

MK-1708 for Healthy Subjects

TF
Overseen ByToll Free Number
Age: 65+
Sex: Any
Trial Phase: Phase 1
Sponsor: Merck Sharp & Dohme LLC

Trial Summary

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.

What is the purpose of this trial?

The purpose of this study is to learn about the safety of MK-1708, and how well elderly people tolerate it. The study will also measure what happens to MK-1708 in a healthy elderly person's body over time (pharmacokinetic or PK study). Researchers will learn if at least 1 dose level of MK-1708 will be safe, well-tolerated, and will be above a certain level in people's blood after 24 hours.

Research Team

SD

Study Director

Principal Investigator

Merck Sharp & Dohme LLC

Eligibility Criteria

This clinical trial is for healthy elderly individuals who have a body mass index (BMI) between 18 and 32 kg/m^2. Participants should be in good health before joining the study.

Inclusion Criteria

I am in good health overall.
My BMI is between 18 and 32.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive multiple doses of MK-1708 or placebo to assess safety, tolerability, and pharmacokinetics

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • MK-1708
Trial Overview The trial is testing MK-1708, a new medication, against a placebo to assess its safety and how well it's tolerated by elderly people. It also measures how MK-1708 behaves in the body over time.
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: MK-1708 Dosage 2Experimental Treatment1 Intervention
Participants receive multiple doses of MK-1708 dosage 2.
Group II: MK-1708 Dosage 1Experimental Treatment1 Intervention
Participants receive multiple doses of MK-1708 dosage 1.
Group III: PlaceboPlacebo Group1 Intervention
Participants receive multiple doses of placebo.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Merck Sharp & Dohme LLC

Lead Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security